PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT)
Phase 1
- Conditions
- oesophageal cancerTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2016-004744-11-NL
- Lead Sponsor
- Academic Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Histologically proven adenocarcinoma of the esophagus or gastro esophageal junc
2. The tumor is surgically resectable
3. Patient is fit for surgery
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20
Exclusion Criteria
Past or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method